. Author manuscript; available in PMC: 2016 Oct 20.

Published in final edited form as: J AIDS Clin Res. 2015 Nov 30;6:525. doi: 10.4172/2155-6113.1000525

Table 3.

Summary of HIV vaccine trials and outcomes.

Author	Vaccine trial (randomised-placebo controlled	Vaccine type	Sample size	Population	Phase	Intended immune response	Results
Flynn et al; 2005 [73]	VAX004	Protein: rgp120	5400	Mostly high-risk MSM	III	Antibodies, CD4+ T cells	6% (-17 to 24)
Pitisuttithum et al; 2006 [74]	VAX003	Protein: rgp120	2500	Injection drug users	III	Antibodies, CD4+ T cells	0.1% ( -30.8 to 23.8)
Rerks-Ngarm et al; 2009 [78]	RV144	Pox/protein: ALVAC/grp120	16,403	Low risk heterosexuals	III	Antibodies, CD4+ & CD8 T cells	31% (1.1-52.1)
Buchbinder, SP et al; 2008 [75]	HVTN 502/Merck 023 (STEP)	Adenovirus type 5 (Ad5) gag/pol/nef	3000	High risk MSM, heterosexual men and women	IIb	CD8+ & CD4+ T cells	HR 1.2 (0.6-2.2)
Gray et al; 2011b [76]	HVTN 503 (Phambili)	Ad5 gag/pol/nef	801; original target of 3000	Heterosexual men and women	IIb	CD8+ & CD4+ T cells	HR 1·25 (0·76-2·05)
Hammer, S 2013 [79]	HVTN 505	DNA-Ad5 gag/pol/nef/env	2504	High risk MSM	IIb	Antibodies, CD4+ & CD8+ T cells	-25% (-121.2 to 29.3)